Park National Corp’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.6M | Sell |
71,820
-1,511
| -2% | -$284K | 0.38% | 72 |
|
|
2026
Q1 | $14.5M | Buy |
73,331
+3,612
| +5% | +$696K | 0.44% | 63 |
|
|
2025
Q4 | $12.8M | Sell |
69,719
-10,081
| -13% | -$1.77M | 0.4% | 65 |
|
|
2025
Q3 | $12.2M | Buy |
79,800
+5,198
| +7% | +$787K | 0.38% | 68 |
|
|
2025
Q2 | $10.4M | Buy |
74,602
+739
| +1% | +$104K | 0.34% | 72 |
|
|
2025
Q1 | $10.9M | Sell |
73,863
-3,203
| -4% | -$463K | 0.4% | 67 |
|
|
2024
Q4 | $10.1M | Buy |
77,066
+455
| +0.6% | +$63.7K | 0.37% | 64 |
|
|
2024
Q3 | $11.9M | Sell |
76,611
-4,080
| -5% | -$659K | 0.42% | 64 |
|
|
2024
Q2 | $12.6M | Buy |
80,691
+9,749
| +14% | +$1.47M | 0.47% | 58 |
|
|
2024
Q1 | $9.61M | Sell |
70,942
-2,131
| -3% | -$282K | 0.37% | 65 |
|
|
2023
Q4 | $9.84M | Buy |
73,073
+3,598
| +5% | +$468K | 0.4% | 68 |
|
|
2023
Q3 | $9.41M | Sell |
69,475
-901
| -1% | -$123K | 0.43% | 66 |
|
|
2023
Q2 | $10.1M | Sell |
70,376
-4,084
| -5% | -$601K | 0.44% | 65 |
|
|
2023
Q1 | $10.3M | Sell |
74,460
-943
| -1% | -$127K | 0.46% | 65 |
|
|
2022
Q4 | $10.2M | Buy |
75,403
+35,029
| +87% | +$4.39M | 0.46% | 63 |
|
|
2022
Q3 | $4.43M | Sell |
40,374
-534
| -1% | -$67.7K | 0.22% | 86 |
|
|
2022
Q2 | $5.41M | Sell |
40,908
-7,077
| -15% | -$929K | 0.26% | 82 |
|
|
2022
Q1 | $6.37M | Sell |
47,985
-6,837
| -12% | -$820K | 0.26% | 80 |
|
|
2021
Q4 | $6.39M | Sell |
54,822
-12,794
| -19% | -$1.51M | 0.25% | 81 |
|
|
2021
Q3 | $8.12M | Sell |
67,616
-15,576
| -19% | -$1.81M | 0.34% | 75 |
|
|
2021
Q2 | $9.97M | Sell |
83,192
-71,756
| -46% | -$7.87M | 0.42% | 70 |
|
|
2021
Q1 | $15.4M | Buy |
154,948
+306
| +0.2% | +$30.8K | 0.68% | 46 |
|
|
2020
Q4 | $15.5M | Buy |
154,642
+3,172
| +2% | +$336K | 0.72% | 44 |
|
|
2020
Q3 | $16.6M | Sell |
151,470
-1,088
| -0.7% | -$121K | 0.87% | 34 |
|
|
2020
Q2 | $16.1M | Sell |
152,558
-6,337
| -4% | -$654K | 0.9% | 33 |
|
|
2020
Q1 | $14.2M | Buy |
158,895
+1,507
| +1% | +$142K | 0.9% | 38 |
|
|
2019
Q4 | $15.7M | Buy |
157,388
+5,039
| +3% | +$474K | 0.8% | 41 |
|
|
2019
Q3 | $13.6M | Buy |
152,349
+13,213
| +9% | +$1.15M | 0.74% | 41 |
|
|
2019
Q2 | $11.5M | Buy |
139,136
+20,196
| +17% | +$1.58M | 0.62% | 44 |
|
|
2019
Q1 | $9.62M | Buy |
118,940
+31,199
| +36% | +$2.46M | 0.54% | 49 |
|
|
2018
Q4 | $6.67M | Buy |
87,741
+50,056
| +133% | +$3.91M | 0.41% | 54 |
|
|
2018
Q3 | $2.98M | Buy |
+37,685
| New | +$2.85M | 0.16% | 90 |
|
Other funds holding AZN
EP
IA
Park National Corp's AZN Position: Q2 2026 in Review
Park National Corp reduced its AstraZeneca (AZN) stake by 2.1% in Q2 2026, selling an estimated $284K and leaving 71,820 shares worth $13.6M. The position accounts for 0.38% of the portfolio, ranked #72.
Park National Corp first reported a position in AZN in Q3 2018 and has held it in 32 quarters since. The position peaked at $16.6M in Q3 2020. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Park National Corp held 71,820 shares of AstraZeneca worth $13.6M as of Q2 2026.
- Park National Corp sold 1,511 AstraZeneca shares in Q2 2026, an estimated $284K.
- AstraZeneca made up 0.38% of Park National Corp's portfolio in Q2 2026, its #72 holding.
- Park National Corp first reported a position in AstraZeneca in Q3 2018 and has held it in 32 quarters since.
- Park National Corp's AstraZeneca position peaked at $16.6M in Q3 2020.
- 1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Park National Corp's 13F filing for Q2 2026, filed 15 Jul 2026.